LeukoStrat® CDx FLT3 Mutation Assay
The only CE-IVD marked assay for selection of acute myeloid leukemia (AML) patients eligible for treatment with midostaurin or gilteritinib fumarate.
We are excited to announce that Invivoscribe has expanded its FLT3 portfolio to include an in-house end-to-end Research Use Only kit for Acute Myeloid Leukemia (AML) measurable residual disease (MRD) research.
The FLT3 ITD MRD MRD Assay is a targeted, deep-sequencing assay identify internal tandem duplications (ITD), the most common mutation of the FLT3 gene1. Unlike flow cytometry assays which require fresh sample and are highly subjective, this assay is designed for use with previously isolated DNA for scalable sample batching and an automated Linux-based software, circumventing the need for costly in-house bioinformatics expertise.
This comprehensive assay enables multiplexing of up to 21 subjects. Generating an objective result at a sensitivity level of 5×10-5, the FLT3 ITD MRD assay enables the use of MRD as a reliable biomarker in longitudinal studies of AML.
FLT3 ITD MRD Assay (MiSeq) (14120019) |
FLT3 ITD MRD v1.2 Software (MiSeq) (14120029) |
Bio-Connect Diagnostics supplies Invivoscribe products in the Benelux. If you have any questions, please contact the helpdesk.
We gladly support you by keeping you updated on our latest products and the developments around our services.